Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Ana, Anavex Life Sciences, Appili, Biogen, Biophytis, Canbridge, Cytodyn, Deciphera, Diurnal, Eisai, Gilead Sciences, Hutchison China Meditech, I-Mab, Kazia, Neurorx, Organicell Regenerative Medicine, Pluristem, Redhill, Relief, Revive, Vaxart.